Retinal Imaging AI Screens for Six Systemic Metabolic and Endocrine Diseases

The escalating prevalence of metabolic syndrome and its associated complications, including type 2 diabetes and hypertension, continues to drive global cardiovascular morbidity and mortality [1, 2]. Current clinical guidelines emphasize the necessity of early detection and intensive management of these risk factors to prevent major macrovascular and microvascular events [3, 4]. However, traditional screening often relies on invasive blood tests and complex diagnostic workflows that can be difficult to scale in resource-limited settings [5]. The retina offers a unique, non-invasive opportunity to visualize the microvasculature and neural tissue, which frequently mirror systemic pathological changes such as oxidative stress and lipid peroxidation [6, 7]. To address the need for accessible diagnostics, researchers have developed an artificial intelligence framework that leverages these retinal biomarkers to provide a rapid, multidisease screening tool directly at the point of care.